Clover Health's Q3 results confirm robust growth and profitability, but unresolved medical cost and star-rating risks keep valuation in check

What happened

Clover Health's latest quarterly update continues to show strong momentum, with revenue growth exceeding 50% year-over-year and GAAP profitability maintained, driven by membership gains and SG&A leverage. The company has raised its full-year 2026 guidance, now expecting $20-$35 million in GAAP net income and $70-$85 million in adjusted EBITDA, reflecting confidence in near-term execution. A key positive is the confirmation of a 5-star PPO rating for payment year 2027, which would boost reimbursement and benefit competitiveness if upheld, but CMS's pending appeal adds uncertainty that the article glosses over. Despite these positives, the stock still trades at a discount to peers on forward sales metrics, yet the master report notes that medical cost inflation remains a concern, with Q2 per-member medical claims rising about 5% year-over-year and BER improving only modestly. The narrative of a turnaround is gaining traction, but the next two quarters must prove that growth is not outrunning unit economics and that the star-rating advantage survives legal challenge.

Implication

Investors should monitor the next quarterly filing for signs that per-member medical claims growth is decelerating and that the insurance benefit expense ratio is stabilizing or improving. The valuation remains reasonable relative to growth, but the stock is no longer cheap enough to overlook the operational risks, especially if the CMS appeal reverses the 5-star rating. A failure to meet the raised guidance or a deterioration in medical cost trends could trigger a sharp multiple compression, given the stock's recent run-up. Conversely, if the star rating is upheld and medical costs stay contained, the path to sustained profitability becomes clearer and the shares could re-rate further. Until these catalysts resolve, the risk-reward is balanced, supporting a wait-and-see approach rather than aggressive buying.

Thesis delta

The new information from the article corroborates Clover's operational strength, with continued membership growth and profitability, but does not address the two main sticking points from the master report: the CMS appeal on the star rating and the elevated PMPM claims growth. The master report's WAIT rating remains appropriate because the stock has already repriced much of the turnaround and the margin of safety is narrow. Therefore, there is no major shift in the investment thesis; it remains contingent on clearer evidence of durable medical cost control and a favorable star-rating resolution.